Temozolomide as salvage treatment in primary brain lymphomas

M. Reni, F. Zaja, W. Mason, J. Perry, E. Mazza, M. Spina, R. Bordonaro, F. Ilariucci, M. Faedi, G. Corazzelli, P. Manno, E. Franceschi, A. Pace, M. Candela, A. Abbadessa, C. Stelitano, G. Latte, A. J M Ferreri

Research output: Contribution to journalArticlepeer-review


Methotrexate (MTX)-based chemotherapy extends survival in patients with primary brain lymphomas, but it is not clear whether multiagent chemotherapy is superior to MTX alone. Treatment options for patients with recurrent primary brain lymphoma are limited; there is no standard second-line chemotherapy. New chemotherapeutic agents with clear activity in brain lymphoma are needed for treatment of recurrent disease. We report the results of a phase II trial assessing activity of the alkylating agent temozolomide in immunocompetent patients with recurrent primary brain lymphomas, previously treated with high-dose MTX-containing chemotherapy and/or radiotherapy. A median of two courses (range 1-12) of temozolomide 150 mg m-2 day-1, for 5 days every 4 weeks was administered to 36 patients yielding nine complete and two partial responses (response rate: 31%; 95% confidence interval 16-46%). One-year survival was 31% (95% confidence interval 16-46%). Toxicity was negligible. We conclude that temozolomide is active in recurrent primary brain lymphomas and should further be evaluated in this disease, perhaps in combination with MTX as initial treatment.

Original languageEnglish
Pages (from-to)864-867
Number of pages4
JournalBritish Journal of Cancer
Issue number6
Publication statusPublished - Mar 26 2007


  • Phase II trial
  • Primary brain lymphoma
  • Salvage therapy
  • Temozolomide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Temozolomide as salvage treatment in primary brain lymphomas'. Together they form a unique fingerprint.

Cite this